Items where authors include "Jayson, GC"

Article

Hollis, RL, Churchman, M, Michie, CO et al. (13 more authors) (2019) High EMSY expression defines a BRCA‐like subgroup of high‐grade serous ovarian carcinoma with prolonged survival and hypersensitivity to platinum. Cancer, 125 (16). pp. 2772-2781. ISSN 0008-543X

O'Connor, JPB, Aboagye, EO, Adams, JE et al. (74 more authors) (2017) Imaging biomarker roadmap for cancer studies. Nature Reviews Clinical Oncology, 14 (3). pp. 169-186. ISSN 1759-4774

Khoja, L, Nolan, K, Mekki, R et al. (14 more authors) (2016) Improved Survival from Ovarian Cancer in Patients Treated in Phase III Trial Active Cancer Centres in the UK. Clinical Oncology, 28 (12). pp. 760-765. ISSN 0936-6555

Zhou, C, Clamp, A, Backen, A et al. (9 more authors) (2016) Systematic Analysis of Circulating Soluble Angiogenesis-Associated Proteins in ICON7 Identifies Tie2 as a Biomarker of Vascular Progression on Bevacizumab. British Journal of Cancer, 115 (2). pp. 228-235. ISSN 0007-0920

Ledermann, JA, Embleton, AC, Raja, F et al. (16 more authors) (2016) Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet, 387 (10023). pp. 1066-1074. ISSN 0140-6736

Oza, AM, Cook, AD, Pfisterer, J et al. (21 more authors) (2015) Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncology, 16 (8). pp. 928-936. ISSN 1470-2045

Adams, M, Calvert, AH, Carmichael, J et al. (20 more authors) (1998) Chemotherapy for ovarian cancer - a consensus statement on standard practice. British Journal of Cancer, 78 (11). pp. 1404-1406. ISSN 0007-0920